The Joint Procurement Office published the official winning results for the 12th batch of National...
Sino Medical Sciences Technology Inc. (SHA: 688108) announced that the COMETIU self‑expanding intracranial drug‑eluting stent...
Hopstem Biotechnology announced the completion of the first close of its nearly RMB 200 million...
Huadong Medicine (SHE: 000963) announced that KIO015 — a novel, patented carboxymethyl chitosan solution for...
Recursion (NASDAQ: RXRX) and Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY), together with its subsidiary...
Kelun-Biotech (HKG: 6990) announced a strategic commercialization agreement with New Frontier Health Technology, a subsidiary...
GenFleet Therapeutics (HKG: 2595) announced that “Kylin‑Flight 01,” the registrational Phase 3 clinical trial of...
Braveheart Bio (NASDAQ: BRVE), a partner of Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG:...
WuXi AppTec Co., Ltd. (SHA: 603259, HKG: 2359) announced that the U.S. District Court for the District...
Salubris Pharmaceuticals (SHE: 002294) announced that its self‑developed innovative siRNA drug SAL0195 has been approved by...
Grand Pharmaceutical Group Limited (HKG: 0512) announced that GPN01530-2, a global innovative radionuclide drug conjugate (RDC)...
Alebund Pharmaceuticals (Jiangsu) Limited (HKG: 9637) announced that the New Drug Application (NDA) for its core...
Sino Biopharmaceutical Limited (HKG: 1177) announced that benmelstobart in combination with chemotherapy, sequentially followed by anlotinib,...
Shenzhen Hybio Pharmaceutical Co., Ltd. (SHE: 300199) announced it has submitted a Class 4 Chemical Abbreviated New...
Daiichi Sankyo Co., Ltd. (TYO: 4568) and Innovent Biologics, Inc. (HKG: 1801) announced an exclusive entrusted promotion...
CARsgen Therapeutics (HKG: 2171) announced that its allogeneic CAR-T cell therapy CT1190B has received clinical...
Transcenta Holding (HKG: 6628) announced a strategic cooperation agreement with WuXi Biologics (HKG: 2269), under...
Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that China’s National Medical Products Administration...
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its self-developed Class 1...
The Category 1 innovative drug Iscartrelvir, jointly developed by Westlake University, Westlake Laboratory, and Westlake...